TB-500 and Gabapentin Interaction: What Women Need to Know

What Is TB-500, and Why Are Women Using It?

TB-500 is a synthetic peptide that corresponds to the active fragment (amino acids 17 to 23) of thymosin beta-4, an endogenous actin-sequestering protein found in virtually every nucleated human cell. It is not FDA-approved for any indication. In the United States, it circulates as a 503A compounded preparation prescribed off-label by some integrative and sports-medicine clinicians for tissue repair, tendon healing, and inflammation.

Women are seeking it for several reasons. Some are managing chronic soft-tissue injuries that have been under-studied in female athletes. Others are exploring it for postpartum pelvic-floor recovery or perimenopausal joint pain. The published evidence is thin.

What the Science Actually Shows

Thymosin beta-4 itself has been studied in animal models of cardiac repair, corneal wound healing, and neurological injury. A 2004 paper by Philp and colleagues in Annals of the New York Academy of Sciences established that the peptide promotes actin polymerization and endothelial cell migration. A small Phase II trial (RegeneRx, NCT00484731) tested thymosin beta-4 eye drops in dry-eye disease. No Phase II or III human trial has been completed for the TB-500 fragment specifically for musculoskeletal repair, and no women-only or women-majority dataset exists.

Women have been historically under-represented in peptide research. Anything you read about TB-500 in women is extrapolated from male-predominant animal data or anecdote. That gap is real, and your prescriber should name it.

How TB-500 Is Typically Dosed

Common compounded protocols circulating in integrative medicine use subcutaneous injections of 2 to 2.5 mg twice weekly for four to six weeks, followed by a maintenance phase of 2 mg twice monthly. These numbers come from practitioner consensus, not a controlled trial. There is no FDA label. There is no pharmacokinetic study in women establishing clearance rate, volume of distribution, or protein binding across the menstrual cycle.

Gabapentin: The Drug You Already Know Well

Gabapentin (brand names Neurontin, Gralise, Horizant) is FDA-approved for postherpetic neuralgia and partial-onset seizures. It is widely prescribed off-label for neuropathic pain, restless leg syndrome, anxiety, insomnia, alcohol withdrawal, and, notably for this audience, menopausal vasomotor symptoms.

ACOG Clinical Practice Bulletin 141 lists gabapentin as a non-hormonal option for hot flashes, particularly for women who cannot use estrogen. A 2006 trial published in Obstetrics & Gynecology found that 900 mg per day of gabapentin reduced hot-flash frequency by 45% compared with placebo. That makes it directly relevant for perimenopausal and postmenopausal women who may simultaneously be using compounded peptides.

Gabapentin Pharmacokinetics in Women

Gabapentin is absorbed via saturable L-amino acid transporters in the small intestine. It does not bind to plasma proteins to any meaningful degree. It is not metabolized by CYP enzymes. It is excreted unchanged by the kidneys: approximately 80% appears in urine as unmodified drug.

Sex differences matter here. Women tend to have lower lean body mass and lower creatinine-based eGFR estimates relative to their true glomerular filtration, which can cause gabapentin to accumulate at "normal" doses. The 2009 MDRD and CKD-EPI equations adjust for sex, but clinicians using older Cockcroft-Gault calculations may underestimate how much gabapentin a woman is actually retaining.

Body fat percentage is also relevant. Higher body fat, which is physiologically normal and more pronounced after menopause, does not affect gabapentin distribution much because the drug distributes into total body water rather than fat. However, a smaller volume of distribution relative to lean body mass means higher peak concentrations per dose for smaller women.

Gabapentin and the Menstrual Cycle

Gabapentin has weak affinity for voltage-gated calcium channels (the alpha-2-delta subunit). Progesterone and its neuroactive metabolite allopregnanolone are positive allosteric modulators of GABA-A receptors. During the luteal phase of the menstrual cycle, when progesterone is highest, you may notice that gabapentin's sedating effects feel stronger. No large trial has formally quantified this, but the mechanistic basis is credible and allopregnanolone's GABA-A modulation is well-documented.

The Interaction: Mechanism by Mechanism

Neither TB-500 nor gabapentin is metabolized by the CYP450 system. TB-500 is a peptide and is presumed to be hydrolyzed by non-specific tissue peptidases. Gabapentin bypasses hepatic metabolism entirely. This means there is no classic CYP-based pharmacokinetic interaction between the two.

P-glycoprotein (P-gp) is equally irrelevant here. Gabapentin is not a P-gp substrate or inhibitor. TB-500's interaction with efflux transporters has not been studied.

Pharmacodynamic Overlap: CNS Sedation

The real concern is pharmacodynamic convergence at the central nervous system. Gabapentin produces dose-dependent sedation, dizziness, and cognitive slowing. These effects are mediated through its action on alpha-2-delta calcium channel subunits in the dorsal horn and brain. The FDA added a warning in 2019 about serious breathing problems when gabapentin is combined with CNS depressants or in patients with respiratory disease.

Thymosin beta-4 has shown neuroprotective and neuroregenerative properties in rodent models of traumatic brain injury and spinal cord injury. A 2012 study in Journal of Neurochemistry demonstrated that systemic thymosin beta-4 administration reduced neuronal apoptosis and promoted oligodendrocyte survival after stroke in male rats. If TB-500 exerts any CNS activity in humans, which remains unconfirmed, additive sedation with gabapentin is biologically plausible.

The honest answer: no published human data directly tests TB-500 plus gabapentin. The additive CNS sedation risk is theoretical but not negligible, especially because gabapentin already carries a black-box-adjacent warning when combined with other CNS depressants.

Renal Overlap: The Understated Risk

Gabapentin requires dose reduction when eGFR falls below 60 mL/min/1.73m². Women lose renal function more slowly than men on average, but the absolute loss after menopause accelerates. If you are postmenopausal and using a compounded peptide that has no renal pharmacokinetic data, your clinician is operating without a safety net on both sides.

TB-500 is a 43-amino-acid peptide (molecular weight approximately 4,900 Da). Peptides of this size are typically filtered by the glomerulus and reabsorbed or catabolized in proximal tubular cells. If renal function is impaired, peptide accumulation is possible in theory. No clinical study has measured TB-500 plasma levels as a function of GFR.

Interaction Severity Classification

Based on the available pharmacology, we can classify this interaction using a framework adapted for compounded peptide combinations that lack formal DDI database entries:

| Interaction Domain | Severity | Evidence Grade | |---|---|---| | CYP450 pharmacokinetic | None identified | N/A (neither drug is CYP substrate) | | P-gp / transporter | None identified | N/A | | CNS sedation (pharmacodynamic) | Low to moderate | Theoretical; supported by gabapentin's known PD + TB-500 animal neuro data | | Renal accumulation | Low to moderate | Theoretical; gabapentin renal label-based | | Immune modulation overlap | Unknown | No human data |

This is not a "never combine" situation. It is a "combine only under active clinical supervision with baseline and periodic monitoring" situation.

How This Interaction Changes Across Your Life Stage

Reproductive Years (Ages 18 to 40)

If you are in your reproductive years and using gabapentin off-label for pain or anxiety while also using TB-500 for injury repair, the primary CNS concern applies at standard doses. Sedation may feel more pronounced in the luteal phase. You should not drive or operate heavy equipment after a new dose of either.

Gabapentin can affect hormonal contraceptive efficacy indirectly. It is a mild inducer of some hepatic enzymes but does not significantly lower ethinyl estradiol levels. The FDA label does not list hormonal contraceptive failure as a documented interaction, but if you are on combined oral contraceptives and gabapentin, check with your prescriber.

Perimenopause (Ages 40 to 55, Approximately)

This is the life stage where the gabapentin-TB-500 combination is most likely to be prescribed together. Gabapentin for hot flashes, joint pain, or sleep disruption is common in perimenopause. TB-500 is being explored for perimenopausal soft-tissue complaints. Declining estrogen reduces muscle mass and increases adipose tissue, which changes the clinical field for both agents.

CNS sensitivity increases in perimenopause. Estrogen withdrawal reduces serotonin, GABA-ergic tone, and dopaminergic signaling, leaving the brain more vulnerable to sedating drugs. A dose of gabapentin that felt manageable at 38 may produce more pronounced cognitive fog at 48 with the same prescription.

Postmenopause

Renal function typically declines by 0.5 to 1 mL/min/1.73m² per year after age 40, meaning many postmenopausal women have an eGFR in the 55 to 70 range without a formal chronic kidney disease diagnosis. If gabapentin is not dose-adjusted for actual eGFR, drug accumulation occurs over weeks. Adding a peptide with no renal dosing data compounds the monitoring problem. Your prescriber should order a basic metabolic panel and urine creatinine before initiating this combination and repeat it at 4 to 6 weeks.

Pregnancy and Lactation: A Required Safety Section

If you are pregnant or planning pregnancy, read this section first.

TB-500 in Pregnancy

TB-500 has no FDA pregnancy category because it is not an FDA-approved drug. There are zero published human studies on thymosin beta-4 peptide fragment use in pregnancy. Animal reproductive toxicology data for TB-500 specifically does not exist in the peer-reviewed literature, though thymosin beta-4 is expressed endogenously at high levels in the placenta, suggesting a physiological role. Using an exogenous compounded peptide to manipulate this system during pregnancy is not supported by any safety data. Avoid TB-500 in pregnancy.

Gabapentin in Pregnancy

Gabapentin carries FDA Pregnancy Category C under the older system. Under the current PLLR labeling, the human data section notes that observational studies have shown an association between gabapentin use in pregnancy and preterm birth, neonatal intensive care unit admission, and small-for-gestational-age birth weight. A 2020 JAMA Internal Medicine cohort study of 4,548 gabapentin-exposed pregnancies found a 29% increase in preterm birth risk compared with unexposed controls.

Gabapentin crosses the placenta. Neonatal withdrawal has been reported. The North American Antiepileptic Drug (NAAED) Pregnancy Registry continues to collect data. If you need gabapentin for a seizure disorder during pregnancy, that risk-benefit calculation differs from using it for hot flashes or sleep. Discuss with your OB-GYN.

Lactation

Gabapentin transfers into breast milk. A 2006 study in Annals of Pharmacotherapy measured an infant relative dose of approximately 1.3 to 3.8%, which is generally considered below the 10% threshold of concern, but infant sedation has been reported with maternal doses above 1,200 mg per day. Monitor the nursing infant for sedation, poor feeding, and abnormal tone.

TB-500 has no published lactation data. Peptides may be denatured in the gut, but transmucosal or systemic absorption by the infant cannot be ruled out. No compounded peptide should be used while breastfeeding without direct discussion with a lactation medicine specialist.

Contraception Requirement

Neither gabapentin nor TB-500 is a teratogen with a mandated REMS-based contraception program, unlike, for example, isotretinoin or valproate. However, given gabapentin's association with adverse pregnancy outcomes and TB-500's complete absence of pregnancy safety data, use of a reliable contraceptive method while on either agent is clinically prudent. Discuss this with your prescriber before starting.

Who This Combination May Be Right For, and Who It Is Not

Potentially Appropriate

• A postmenopausal woman using gabapentin 300 mg at bedtime for hot flashes, with eGFR above 60, no respiratory disease, and stable renal function, who wants to add TB-500 for a diagnosed tendon injury, under close prescriber monitoring.
• A perimenopausal woman using gabapentin for neuropathic pain who starts TB-500 at a compounding pharmacy with a prescribing physician tracking both agents, with baseline CNS and renal assessment.

Likely Inappropriate

• Any pregnant woman. Both agents carry unacceptable uncertainty in pregnancy.
• A breastfeeding woman, given gabapentin's measurable milk transfer and TB-500's unknown transfer.
• A woman with eGFR below 30 mL/min/1.73m², where gabapentin accumulation risk is high and TB-500's renal handling is undefined.
• A woman using other CNS depressants (opioids, benzodiazepines, alcohol dependence treatment with naltrexone plus sedating adjuncts) alongside this pair, given additive sedation risk.
• A woman obtaining TB-500 without a prescribing clinician, from gray-market peptide vendors, where purity, sterility, and actual peptide identity are not verified.

Monitoring and Practical Clinical Steps

Before starting this combination, ask your prescriber to order:

1. Basic metabolic panel including serum creatinine and calculated eGFR (to set gabapentin dose and establish a TB-500 renal baseline).
2. A sedation and fall-risk assessment, especially if you are postmenopausal, take any other CNS-active medication, or have a history of balance problems.
3. A medication reconciliation, because gabapentin is also present in the combination products Horizant (gabapentin enacarbil) and Gralise, and women sometimes take these alongside compounded gabapentin without realizing it.

Repeat the basic metabolic panel at 4 to 6 weeks after starting and then every 3 months if both agents are continued long-term.

Track sedation using a simple daily 1 to 10 scale in a notes app. If daytime sedation exceeds a 4 on two consecutive days, contact your prescriber before the next TB-500 injection.

Two clinician-level statements anchor this guidance. The FDA's 2019 Drug Safety Communication states directly: "Gabapentinoids can cause serious breathing problems when taken with other drugs that depress the central nervous system, including opioids, and in patients with underlying respiratory disease." And The Menopause Society's 2023 position statement on non-hormonal therapies notes that gabapentin's evidence base for vasomotor symptoms "includes risks of somnolence, dizziness, and peripheral edema that should be reviewed with each patient," a reminder that the drug's side-effect profile is not trivial even as monotherapy.

Specific Numbers Your Prescriber Should Know

• Gabapentin dose adjustment thresholds per FDA label: eGFR 30 to 59, reduce total daily dose by 50%; eGFR 15 to 29, reduce by 75%; eGFR <15, use 300 mg every other day as a starting point.
• TB-500 common compounded dose: 2 to 2.5 mg subcutaneous twice weekly (no FDA-validated dose exists).
• Gabapentin infant relative dose in breast milk: 1.3 to 3.8%, measured at maternal doses of 900 to 2,100 mg per day.
• 45% reduction in hot-flash frequency with gabapentin 900 mg/day vs placebo in the Guttuso 2006 trial (n=234).